Body Fluid Exosome & Tissue Exosome Combined Research Service
- Exosome extraction from tissues: By combining differential centrifugation, ultracentrifugation, size-exclusion chromatography, and ultrafiltration, we optimize exosome recovery from various tissue types (e.g., tumor, brain, liver) while minimizing non-vesicular contaminants.
- Enrichment from body fluids: Tailored extraction protocols are developed for plasma, serum, cerebrospinal fluid (CSF), and other fluid types to ensure exosome integrity and functionality.
- Integrated omics analysis: Covers exosomal proteomics, lipidomics, metabolomics, and next-generation sequencing (RNA/DNA) for a comprehensive molecular landscape.
- Tissue-fluid correlation analysis: Bioinformatics comparison highlights molecules co-present in both diseased tissues and body fluids, helping exclude non-specific background signals.
- Our proprietary tissue-derived exosome isolation workflow overcomes common challenges such as high vesicle breakage and residual contaminants.
- Multi-platform validation (NTA, flow cytometry, TEM) ensures precise and reliable exosome characterization.
Although non-invasive liquid biopsy techniques based on body fluids such as blood and urine offer substantial potential for early disease diagnosis and dynamic monitoring, current technologies still face a significant bottleneck—the complexity of exosome origins in body fluids. These vesicles, originating from diverse cells and tissues throughout the body, are widely present in blood, urine, cerebrospinal fluid, saliva, pleural effusion, ascites, bone marrow, seminal fluid, milk, cervical fluid, and feces, leading to dilution of disease-specific exosomal signals by substantial background noise. For instance, tumor-derived exosomes may constitute less than 1% of the circulating exosomes, severely limiting the sensitivity and specificity of diagnostic biomarkers.
Liang X, et al. Cancer Screen Prev. 2025.
Fig. 1. Sources of Human Biofluids and Their Clinical Applications
In contrast, traditional tissue biopsies, though capable of directly reflecting the actual state of the disease microenvironment, are difficult to widely adopt clinically due to their invasive nature and sampling limitations. To address this challenge, researchers are actively exploring integrated strategies combining tissue-derived exosomes with fluid-derived exosomes. By merging the specificity of tissue-exosome information with the accessibility advantage of circulating exosomes, these combined analyses aim to improve precision in disease detection, diagnosis, treatment monitoring, and prognostic evaluation, thereby accelerating the clinical translation of liquid biopsy technologies.
Services at MtoZ Biolabs
To address this challenge, MtoZ Biolabs has launched Body Fluid Exosome & Tissue Exosome Combined Research Service which combines the specificity of tissue-derived exosomal signals with the accessibility of circulating exosomes in body fluids. This integrated approach supports researchers in identifying biomarkers with both high sensitivity and tissue specificity, offering reliable targets for translational medicine. Our services include, but are not limited to:
1. High-Purity Exosome Isolation
2. Multi-Omics Profiling
3. Clinically Oriented Biomarker Validation
Based on the molecular features of candidate biomarkers, we provide downstream validation assay designs (e.g., ELISA, single-vesicle flow cytometry) to accelerate clinical translation feasibility.
Service Advantages
1. Technical Expertise
2. Multi-Omics Integration
Deep proteome coverage (identifying up to 10⁴ proteins) combined with global lipidomic and metabolomic profiling reveals comprehensive regulatory networks of exosomal function.
3. End-to-End Workflow
From sample preparation and data analysis to preclinical biomarker validation, we offer a fully integrated solution that shortens R&D timelines.
Applications
1. Early Cancer Screening and Subtyping
By comparing miRNA profiles between tumor tissues and paired plasma exosomes, novel non-invasive diagnostic biomarkers can be identified to differentiate cancer subtypes (e.g., lung vs. colorectal cancer).
2. Neurological Diseases
Integrated analysis of CSF and brain tissue exosomes enables the discovery of dynamic biomarkers for neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.
3. Fibrosis and Inflammation Monitoring
Common exosomal signals from liver/lung tissues and serum can help develop organ-specific fibrosis progression prediction models.
4. Therapeutic Resistance Mechanism Studies
By revealing the communication pathways between drug-resistant tumor tissue exosomes and circulating exosomes, this approach informs optimized combination therapy strategies.
As liquid biopsy moves closer to clinical application, single-dimensional exosome analysis is no longer sufficient for the demands of precision medicine. MtoZ Biolabs leverages integrated profiling of tissue and fluid-derived exosomes to overcome the “specificity bottleneck” in biomarker discovery, offering innovative tools for early disease warning, personalized therapy, and treatment monitoring. Whether you're a basic researcher or a translational medicine team focused on diagnostic development, our cross-dimensional exosome platform empowers your progress from research to clinical success. Contact MtoZ Biolabs now for customized project planning and expert technical consultation—and take the next step toward exosome biomarker breakthroughs!
How to order?
